ライフサイエンスコーパス: symptom onset

1 , 16.2 versus 6.8 years before the estimated symptom onset).

2 the latest time interval tested (>20 d after symptom onset).

3 age diagnostic delay is up to 5-6 years from symptom onset.

4 g severity who presented within a week after symptom onset.

5 lymerase chain reaction (PCR) >30 days after symptom onset.

6 less than 1% of transmission occurred before symptom onset.

7 oxygen support, at a median of 25 days after symptom onset.

8 ive procedures and when performed soon after symptom onset.

9 e optimal time window of the treatment after symptom onset.

10 virus 2 infection, grouped by interval since symptom onset.

11 alse-negative rate by day since exposure and symptom onset.

12 ith receiving treatment within 24 hours from symptom onset.

13 by orders of magnitude within a few days of symptom onset.

14 r to 30% of infected cases within 48 h after symptom onset.

15 nterpretation of the test, such as time from symptom onset.

16 ng patients with lesion age < 4.5 hours from symptom onset.

17 birth has been correlated to patient age at symptom onset.

18 ndings peaked at 10-12 days from the date of symptom onset.

19 en treatment was started within 7 days after symptom onset.

20 nd genetic factors associated with period of symptom onset.

21 ementia Rating scores and estimated years to symptom onset.

22 the semen of the survivors after 9 months of symptom onset.

23 early as their 30s, decades before expected symptom onset.

24 om respiratory failure within 3-5 years from symptom onset.

25 onsolidation which peaked at 10-12 days from symptom onset.

26 0.13) using samples collected >14 days after symptom onset.

27 or treatment delayed as long as 3 days after symptom onset.

28 n-QW despite treatment within 12 hours after symptom onset.

29 iverge already at 17.8 years before expected symptom onset.

30 rapeutic disease-modifying time window after symptom onset.

31 rwent follow-up unenhanced CT 24 hours after symptom onset.

32 .5%) of patients presented within 2 weeks of symptom onset.

33 r first medical help later than 30 min after symptom onset.

34 d involvement of the fellow eye 1 year after symptom onset.

35 nd stroke mimics (n = 20) within 24 hours of symptom onset.

36 before development of TBM-IRIS through IRIS symptom onset.

37 ntion and presenting less than 12 hours from symptom onset.

38 favorably in patients presenting early after symptom onset.

39 s had IVT started within 4.5 hours of stroke symptom onset.

40 or endovascular therapy up to 18 hours after symptom onset.

41 l delay in the one individual treated before symptom onset.

42 to NCs, starting 11.2 years before expected symptom onset.

43 ells) or placebo between 24 h and 48 h after symptom onset.

44 for days 2-90, given orally) within 24 h of symptom onset.

45 in spinal MNs of TDP-43-driven ALS at motor symptom onset.

46 ATXN1 mRNA by rAAV.miS1 when delivered after symptom onset.

47 by stroke specialists within 24 hours after symptom onset.

48 everse disease readouts when delivered after symptom onset.

49 ated with increased WMH well before expected symptom onset.

50 crease approximately 6 years before expected symptom onset.

51 controls, more than 15 years before expected symptom onset.

52 rresponds to the second and third week after symptom onset.

53 ion corresponding to day 10 (IQR 8-12) after symptom onset.

54 se with atrophy and hypometabolism closer to symptom onset.

55 carriers (preHD) far from predicted clinical symptom onset.

56 ayed, i.e., 3 days or longer) with regard to symptom onset.

57 reshold (Ct) value was >30 or >14 days after symptom onset.

58 f the first positive nucleic acid test after symptom onset.

59 sitivity to >80% between days 6 and 10 after symptom onset.

60 ission between 0.5 and 8.0 hours after known symptom onset.

61 e viral load-time AUC lies within 10 days of symptom onset.

62 able among persons tested up to 90 days post symptom onset.

63 two individuals, most prominently the age of symptom onset.

64 S-CoV-2 spike protein at least 2 weeks after symptom onset.

65 on-carriers from 16 years prior to estimated symptom onset.

66 % CI, 85.0%-98.3%) for samples >14 days post symptom onset.

67 ues <26) and were obtained within 21 days of symptom onset.

68 oV-2-specific serum IgA and IgG titers after symptom onset.

69 d using samples collected 7 to 14 days after symptom onset.

70 2.5 or 3.5 and with more transmission before symptom onset.

71 ative or became positive 12 to 14 days after symptom onset.

72 olds (Ct) occurring 9, 26, and 36 days after symptom onset.

73 patients were enrolled within 12 hours from symptoms onset.

74 proved to be predictive of postoperative DED symptoms onset.

75 ive and at least two weeks have passed since symptom onset; 2) assessment of multisystem inflammatory

76 Patients presenting within 4 weeks of symptom onset (30 with diabetes mellitus, 62 control pat

77 t one symptom after a mean of 125 days after symptoms onset, 33.3% reported one or two symptoms and 1

78 as started within a median of 285 minutes of symptom onset; 51 (41%) patients achieved a mTICI 2b, an

79 ts had abnormal MRI findings 2-4 weeks after symptom onset (58.9%), including 17 with acute ischemic

80 al sensitivity during the first 5 days after symptom onset, 70%-71% from Days 9 to 11, and 30% at Day

81 CI 87.3-99.4%) compared with after 7 days of symptom onset (75.0%, 95% CI 61.4-85.2%).

82 hain reaction negativity was 46.4 days after symptom onset (95% confidence interval, 11-82.6).

83 eceived medical help later than 30 min after symptom onset, adrenaline auto-injector prescription is

84 SFI) and assess its predictive value for DED symptom onset after cataract surgery.

85 Median symptom onset age was 44 years (range = 8-103), and 54%

86 ve cohort study, we collected data on age at symptom onset, age at death, and disease duration for pa

87 es by doing an international study of age at symptom onset, age at death, and disease duration in ind

88 the upper airway prior to or at the time of symptom onset, an unusual feature that has enabled wides

89 19.8 days +/- 6.1 (95% CI: 18.1, 20.2) after symptom onset and 10.5 days +/- 3.8 (95% CI: 10.2, 12.9)

90 ence was estimated to be 79% one month after symptom onset and 64% after 400 days.

91 ample mean (SD) age was 64.1 (10.3) years at symptom onset and 67.9 (9.9) years at Three Words Three

92 trol for confounders: age, sex, time between symptom onset and admission <= 7 days, Charlson comorbid

93 for sex, the TBI+ bvFTD group had an age of symptom onset and age of diagnosis that was on average 2

94 Our study showed that age at symptom onset and at death of people with genetic fronto

95 Mean age at symptom onset and at death was 49.5 years (SD 10.0; onse

96 could identify mutation carriers approaching symptom onset and capture rates of brain atrophy.

97 ittsburgh compound B PET, estimated years to symptom onset and Clinical Dementia Rating Scale-Sum of

98 hat sensitivity reached 100% at day 17 after symptom onset and day 13 after PCR positivity.

99 Infectiousness peaks around a day before symptom onset and declines within a week of symptom onse

100 spiratory specimens peak by 2 or 3 days from symptom onset and decrease rapidly thereafter.

101 y (TBI) is associated with an earlier age of symptom onset and diagnosis in a large sample of patient

102 agnosis is associated with an earlier age of symptom onset and diagnosis in patients with bvFTD.

103 ose with a delay of less than 1 year between symptom onset and diagnosis.

104 nk in the stroke rescue chain, starting with symptom onset and ending with recanalisation, should be

105 NF slowed disease, doubling the time between symptom onset and endstage.

106 time-dependent local immune responses before symptom onset and explaining the as-yet unpredictable ou

107 In CRVO patients, even minor delays between symptom onset and first injection led to less optimistic

108 vidual progressive phenotypes than on age at symptom onset and for clinical trials will help optimize

109 c development, requiring long delays between symptom onset and formal diagnosis.

110 s and related products in the 90 days before symptom onset and had pulmonary infiltrates on imaging a

111 antigens in 95% of patients by 4 weeks after symptom onset and IgG to the RBD increased until the thi

112 pa = 0.78) after greater than 1 hour between symptom onset and imaging, which increased to high agree

113 lable in 13 subjects, NPTX2 decreased around symptom onset and in the symptomatic stage.

114 neurofilament-heavy chain) are normal before symptom onset and increased by at least an order of magn

115 As this precedes symptom onset and is evident despite normal task perform

116 The delay between symptom onset and isolation had the largest role in dete

117 nal analysis at baseline showed that earlier symptom onset and longer duration since onset was associ

118 on of gamma-MNs in SOD1(G93A) mutants delays symptom onset and prolongs lifespan, demonstrating a pat

119 ts was based on a sliding scale depending on symptom onset and ranged from 1 to 4 years.

120 nd IgG antibodies in 5-d time intervals from symptom onset and studied the specificity of each assay

121 level data regarding infectiousness prior to symptom onset and the asymptomatic proportion among all

122 ase ascertainment rate and the delay between symptoms onset and death.

123 serum samples collected 6 or more days after symptom onset (and the immunoglobulins M and G in all 33

124 patients with acute NAION (within 14 days of symptom onset) and 15 control patients with age-related

125 a expansion, all occurring within 48 h after symptom onset) and five (19%) of 27 in the PCC group (no

126 33 samples collected at least 15 days after symptom onset), and correctly classified 456 out of the

127 In this retrospective study, we examined symptom onset, and genetic and neuropathological data fr

128 ed subgroups stratified by age, sex, time of symptom onset, and known ischemic heart disease.

129 symptom onset and declines within a week of symptom onset, and no late linked transmissions (after a

130 rrelation between IgG avidity and days since symptom onset, and peak readings were significantly high

131 tandem with immunoglobulin titers following symptom onset, and positive percent agreement between de

132 proportion seeking treatment within 1 day of symptom onset, and presence of primary proliferative vit

133 relationships of baseline Q waves, time from symptom onset, and reperfusion strategy with in-hospital

134 Demographic characteristics, symptom onset, and rotavirus vaccine status were ascerta

135 portion of transmission that occurred before symptom onset, and the proportion of subclinical infecti

136 .7%) cases likely transmitted TB well before symptom onset, and these were largely sputum negative at

137 as age of onset younger than 65 years, rapid symptom onset, and/or impairment in multiple cognitive d

138 At >14 days after symptom onset, antibodies against SARS-CoV-2 nucleocapsi

139 he following variables: variant type, age at symptom onset (AO), and clinical phenotype.

140 tures, investigated associations with age at symptom onset, APOE genotype, and mutation position, and

141 fection when measured at least 14 days after symptom onset, are associated with clinical severity, an

142 atus defined by days between vaccination and symptom onset as the predictor.

143 of pathology with group, estimated years to symptom onset, as well as cross-modal relationships.

144 t 90 days in patients enrolled within 3 h of symptom onset, assessed in the intention-to-treat popula

145 d that both females and males can experience symptom onset at any age.

146 he age period of self-reported atopic eczema symptom onset based on repeated measures of self-reporte

147 with 2 reported incidents of pertussis with symptom onset between 1 January 2010 and 31 December 201

148 ively, when performed 14 days or later after symptom onset, but sensitivity decreased at earlier time

149 Still, treatment following symptom onset can be effective; Glut1 repletion in early

150 MR was performed within the first week after symptom onset (CMR-I) and repeated after 6 months (CMR-I

151 ificant difference was observed in age, sex, symptom onset, comorbidities, tumor history, use of resp

152 , an R(0) of 1.5, and 0% transmission before symptom onset could be controlled even with low contact

153 ient with COVID-19 on or after the patient's symptom onset date.

154 days of infection before the typical time of symptom onset (day 5), the probability of a false-negati

155 early oseltamivir treatment (<=48 hours from symptom onset) decreases mortality compared to late trea

156 uding site of onset (bulbar or limb), age at symptom onset, delay from onset to diagnosis and the use

157 nd a documented fundus examination at visual symptom onset demonstrated optic disc edema.

158 approximately 12.5 years before the expected symptom onset determined on an individual basis.

159 Data were collected regarding symptom onset, diagnostic testing results, and conversio

160 clinical data available on sex, age at motor symptom onset, disease duration (from motor symptom onse

161 At symptom onset, distinguishing the disease from a primary

162 rmed COVID-19 cases sampled at >14 days post-symptom onset (DPSO), whereas the salivary anti-receptor

163 ipants with COVID-19 symptoms (<=7 days from symptom onset [DSO], >=18 years of age) were utilized to

164 uch defects was increased among women with a symptom onset early in pregnancy.

165 focal dystonia evaluated within 5 years from symptom onset, enrolled in the Natural History Project o

166 c memory as a function of estimated years to symptom onset (EYO) were analyzed.

167 rofilament light and estimated years to/from symptom onset (EYO), as well as years to/from actual ons

168 PINK1, LRRK2 and SNCA in relation to age at symptom onset, family history and clinical features.

169 cs and dates and times of possible exposure, symptom onset, fever onset, and hospitalization.

170 ool specimens collected within 7 days of AGE symptom onset for clinician-requested diagnostic testing

171 ore, current strategies that rely solely on "symptom onset" for infection identification need urgent

172 ted with intravenous tPA within 4.5 hours of symptom onset from 888 surveyed hospitals between June 2

173 onance at 1.5 T seven days (5-10 days) after symptom onset (FU0), after 5 weeks (FU1), and after 6 mo

174 ICP at 9-15 weeks of gestation and prior to symptom onset (group 1 cases/samples: ICP n = 35/80, unc

175 onset < 34 weeks) and late-onset PE (LO-PE; symptom onset > 34 weeks) cohorts.

176 d neurological onset earlier after prodromal symptom onset, had milder weakness, showed more rapid im

177 associated with less years before estimated symptom onset, higher global Abeta brain burden, and wit

178 to access treatment within the first day of symptom onset, if the association is fully causal.

179 ithin 12 hours and again at 48+/-24 hours of symptom onset in 172 patients with imaging-confirmed AIS

180 used chart-confirmed cases with adjudicated symptom onset in a self-controlled risk interval (SCRI)

181 m onset in North America and within 4.5 h of symptom onset in all other countries.

182 l interval (SI), defined as the time between symptom onset in an infector and infectee pair, is commo

183 cerebral blood flow and the expected age of symptom onset in carriers, but not non-carriers.

184 d by at least an order of magnitude at early symptom onset in CSF (pNF-H) or serum and CSF (NF-L).

185 estimating R for the case with the earliest symptom onset in each cluster (Rindex).

186 s closer to and beyond their expected age of symptom onset in key frontotemporal dementia signature r

187 lination and neurodegeneration often precede symptom onset in multiple sclerosis (MS).

188 thrombolysis (alteplase bolus) within 3 h of symptom onset in North America and within 4.5 h of sympt

189 VID-19 cases could have been detected before symptom onset in real time via a two-tiered warning syst

190 s also altered in vivo in spinal cord before symptom onset in SBMA mice, and crucially in motor neuro

191 nd PLEKHB1 to be deregulated in MNs at motor symptom onset in TDP-43-driven ALS models.

192 m onset in the risk interval and 51 cases of symptom onset in the control interval were identified.

193 Sixteen cases of symptom onset in the risk interval and 51 cases of sympt

194 iratory tract ceases after 2 to 3 weeks post-symptom-onset in most patients.

195 patients were assigned within 24 hours after symptom onset, in a 1:1 ratio, to receive a 30-day regim

196 , acquired at a mean of 11 +/- 10 days after symptom onset, in addition to follow-up scans of 16 pati

197 ic medication use, on AR symptoms and asthma symptoms/onset, in patients with birch pollen-associated

198 alysed genotypic and phenotypic data (age at symptom onset, initial cognitive or behavioural symptoms

199 cation, head CT performed within 72 hours of symptom onset, initial DS angiographic results negative

200 The average time from exposure to symptom onset is 5 days, and 97.5% of people who develop

201 Loss of consciousness at symptom onset is an important manifestation of early bra

202 period between immunization and EAE's overt symptom onset is characterized by distinct host response

203 Widespread neuropathology prior to symptom onset is consistent with patient studies, wherea

204 les well-informed prospective studies, since symptom onset is near certain and age of onset is predic

205 roup analysis, treatment within 7 days after symptom onset led to lower 90-day mortality than use of

206 tures associated with early-onset PE (EO-PE; symptom onset < 34 weeks) and late-onset PE (LO-PE; symp

207 domly assigned patients (1:1:1 stratified by symptom onset </=4 days or 5-6 days) to receive 300 mg o

208 levation myocardial infarction within 6 h of symptom onset (<2 h, n = 107; >=2 h but <4 h, n = 235; >

209 cation of independent predictors of risk for symptom onset may guide education and clinical managemen

210 X levels were associated with earlier age of symptom onset (median ePPIX levels for those who develop

211 sented to the hospital within 24 hours after symptom onset (median time from symptom onset to blood s

212 C allele was associated with a higher age at symptom onset (median years A/A 63.5, A/C 65.6, and C/C

213 In most people with narcolepsy, symptom onset occurs between the ages of 10 and 35 years

214 sign) was a good predictor of ocular surface symptom onset (odds ratio, 9.45; 95% confidence interval

215 ss starts one to two decades before expected symptom onset of ADAD.

216 predict progression from normal cognition to symptom onset of mild cognitive impairment or dementia:

217 nd calculated daily sensitivity from date of symptom onset or first positive test.

218 rum samples collected more than 14 days post-symptom onset or post-initial positive reverse transcrip

219 Serum and urine collected within 4 weeks of symptom onset or within 6 weeks of travel were tested wi

220 1.5-27.8) and those treated > 6 hours after symptom onset (OR = 13.7, 95% CI = 1.4-140).

221 point prevalence of SARS-CoV-2 and assessed symptom onset over 30-day follow-up to determine: (1) th

222 d more effective when performed sooner after symptom onset (p = 0.04, 12 studies).

223 e slightly increased from 14 to 90 days post symptom onset (p=0.06).

224 Patient demographics, time of symptom onset, presenting clinical features, management,

225 wenty-two of those patients (78.6%) reported symptom onset prior to or in conjunction with the molecu

226 measures become abnormal around the time of symptom onset, prior to diagnosis, and may be of value f

227 both IgG and IgM occurs around 12 days post-symptom onset (range 1-40), with extensive individual va

228 pic eczema during a given year, only 38% had symptom onset reported in childhood.

229 bitor of extracellular PPIA, MM218, given at symptom onset, rescued motor neurons and extended surviv

230 oss of lean mass, and their inhibition after symptom onset reverses anorexia.

231 edian time to baseline visit, 358 days after symptom onset), six symptoms were reported significantly

232 hat TB transmission can occur before patient symptom onset, suggesting also that TB transmits during

233 Viral shedding is highest before symptom onset, suggesting high transmissibility before s

234 levels potentially increasing just prior to symptom onset, suggesting that GFAP may be an important

235 ismatch profile treated up to 18 hours after symptom onset supports a randomized trial of endovascula

236 tients around the time of, or shortly after, symptom onset the H-reflex was lost.

237 On the day of symptom onset, the median false-negative rate was 38% (C

238 20% (CI, 12% to 30%) on day 8 (3 days after symptom onset) then began to increase again, from 21% (C

239 s can be more frequent, along with shortened symptoms onset time.

240 Of the area under the curve (AUC) spanning symptom onset to 30 days, 96.9% lay within the first 7 d

241 n probabilities increase from roughly 10% at symptom onset to 98-100% by day 22, after which IgM wane

242 Median time from symptom onset to arterial puncture was 227 minutes (inte

243 the test varies with time from exposure and symptom onset to avoid being falsely reassured by negati

244 hours after symptom onset (median time from symptom onset to blood sampling = 3.3 hours; interquarti

245 Survivors had shorter duration from symptom onset to cannulation (12.5 days vs. 19.9 days, p

246 Ischemic time, defined as the time from symptom onset to coronary reperfusion, was a pre-specifi

247 The mean duration from symptom onset to culture positivity was 4.5 days (range

248 symptom onset, disease duration (from motor symptom onset to death or to the date of censoring, Dec

249 Shorter disease duration from cognitive symptom onset to death was observed in men (beta, -0.73;

250 60.9 years (IQR 52.7-68.2), median time from symptom onset to diagnosis was 1.01 years (IQR 0.67-1.67

251 Stroke Scale [NIHSS] = 16, median time from symptom onset to endovascular therapy = 5.2 hours).

252 SARS-CoV-2 infection, with an interval from symptom onset to enrolment of 12 days or less, oxygen sa

253 A delay from symptom onset to first injection of 30 days or more pred

254 For CRVO patients, more time from symptom onset to first injection predicted less optimist

255 significant difference in the duration from symptom onset to groin puncture (254 minutes for the IVT

256 Mean (SD) total delay from symptom onset to initiation of treatment was 407 (665) d

257 y of control decreases with long delays from symptom onset to isolation, fewer cases ascertained by c

258 c reproduction number (R(0)), the delay from symptom onset to isolation, the probability that contact

259 versus 10.0%), consistent across times from symptom onset to presentation (15.4% versus 9.9% </=3 ho

260 5 years [SD, 13.1]; women, 47.0%), time from symptom onset to randomization was 196 minutes (IQR, 142

261 1.82) Log10 copies/mL, and median time from symptom onset to randomization was 3 days.

262 lts In the stent retriever arm of the study, symptom onset to reperfusion time of 150 minutes led to

263 scenario analyses, we varied the delay from symptom onset to self-isolation, the proportion of sympt

264 eshold (Ct) values from respiratory samples, symptom onset to test (STT), and infectivity in cell cul

265 demonstrate a significantly longer time from symptoms onset to hospital admission among patients with

266 Median (interquartile range) time from symptoms onset to hospital admission was significantly l

267 l 1) in 2018 and 2019, in terms of time from symptoms onset to hospital admission, clinical character

268 Times of symptom-onset-to-baseline-CT (hr) (median [interquartile

269 ubacute stroke (3-14 days after neurological symptom onset) underwent MRI examination.

270 tery were included less than 4.5 hours after symptom onset using standard intravenous thrombolysis el

271 While the mean age at symptom onset was 0.8 +/- 0.6 years [standard deviation

272 For the RP patients, the median age at symptom onset was 4.0 years.

273 Patients' mean (SD) age at symptom onset was 4.4 (4.4) years.

274 Symptom onset was 9-20 days after treatment initiation,

275 The date of reported bursitis symptom onset was abstracted from the medical record.

276 The median duration between exposure and symptom onset was approximately 1 day.

277 but neither histopathology nor the speed of symptom onset was associated with a poor prognosis.

278 HBAT administration within 2 days of symptom onset was associated with shorter hospital and i

279 Treatment with BAT product at <=2 days of symptom onset was associated with shorter hospital and I

280 he association of viral load with days since symptom onset was examined in a multivariable regression

281 Age at NSF symptom onset was reported for 177 patients (mean, 49 ye

282 ymptoms (>40 years); the mean age for asthma symptoms onset was 30.2 years and for asthma diagnosis 3

283 T-confirmed acute ICH scanned within 48 h of symptom onset, we investigated the sensitivity and speci

284 n the anterior circulation within 6 hours of symptom onset were included.

285 Viral loads by day since symptom onset were predicted using the model and transmi

286 ic stroke who could be treated within 8 h of symptom onset were randomly assigned to medical therapy

287 later intervention (<3 versus >3 months from symptom onset) were associated with CA3 atrophy.

288 had CT angiography within 6 and 12 hours of symptom onset, were categorized according to the occlusi

289 ed from 2 days to a maximum of 6 weeks after symptom onset, whereas Mp DNA and antibodies persisted u

290 These plaques form 10-20 years before AD symptom onset, whereas robust tau pathology is more clos

291 nfirmed cases with identifiable exposure and symptom onset windows to estimate the incubation period

292 logical sensitivity increased with days post symptom onset with >50% of patients seropositive by at l

293 sensitivity of PCR decreased with days post symptom onset with >90% clinical sensitivity during the

294 ntiating between ICH and IS within 4.5hrs of symptom onset with a sensitivity of 61% and a specificit

295 information, 22 were detected before (or at) symptom onset, with four cases detected at least nine da

296 % CI, 81.8%-96.7%) for samples >14 days post symptom onset, with specificity 94.4% (95% CI, 89.2%-97.

297 water uptake identifies stroke patients with symptom onset within 4.5 hours with high accuracy and ma

298 drome coronavirus 2 infection, with COVID-19 symptom onset within 7 days and oxygen saturation of 92%

299 and further characterise subtypes by time of symptom onset within pregnancy and three post-partum per

300 Self-isolation by 20% of cases 24 h after symptom onset would delay and flatten the outbreak traje